Overview

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Status:
Terminated

Trial end date:
2020-07-16

Target enrollment:

Participant gender:

Summary

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.

Phase:

Phase 2

Details

Lead Sponsor:

F-star Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.

Collaborator:

PRA Health Sciences